These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 10717776

  • 21. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin.
    Song S, Chen JK, He ML, Fotherby K.
    Contraception; 1989 Apr; 39(4):385-99. PubMed ID: 2498034
    [Abstract] [Full Text] [Related]

  • 22. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol.
    Cullberg G.
    Acta Obstet Gynecol Scand Suppl; 1985 Apr; 133():1-30. PubMed ID: 3161265
    [Abstract] [Full Text] [Related]

  • 23. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
    Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier J.
    Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ.
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [Abstract] [Full Text] [Related]

  • 25. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
    Palatsi R, Reinilä M, Kivinén S.
    Acta Derm Venereol; 1986 Nov; 66(3):225-30. PubMed ID: 2426899
    [Abstract] [Full Text] [Related]

  • 26. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylöstalo P.
    Acta Derm Venereol; 1984 Nov; 64(6):517-23. PubMed ID: 6084924
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS, Ayerst RI, Harris JW, Stone RA, Anderson AE, Jones TL, Curtis MK.
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [Abstract] [Full Text] [Related]

  • 28. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
    Aden U, Jung-Hoffmann C, Kuhl H.
    Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
    [Abstract] [Full Text] [Related]

  • 29. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A, Stoy DB, LaRosa JC, Muesing RA, Cleary PA, Miller VT, Gilbert PR, Stadel B.
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial.
    Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME.
    J Am Acad Dermatol; 2002 Sep; 47(3):399-409. PubMed ID: 12196750
    [Abstract] [Full Text] [Related]

  • 31. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M, Almström E, Högstedt S, Nabrink M.
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [Abstract] [Full Text] [Related]

  • 32. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
    Wilson ES, Cruickshank J, McMaster M, Weir RJ.
    Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
    [Abstract] [Full Text] [Related]

  • 33. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
    Crona N, Silfverstolpe G, Samsioe G.
    Contraception; 1984 Mar; 29(3):261-70. PubMed ID: 6234148
    [Abstract] [Full Text] [Related]

  • 34. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ, Buret J, Gillain D, Romus MA, Lambotte R.
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E, Fraser IS, Lacarra M, Mishell DR, Alvarez F, Brache V, Nash HA.
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W, al-Yacoub G, Fuhrmeister A.
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [Abstract] [Full Text] [Related]

  • 39. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M, Kitchens CS, Khan FY.
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.